GLP-1 pipeline, trials, approvals and supply.
Taken directly from public records and refreshed multiple times daily: what is in development, when trials are due to report, what the FDA and EMA have decided, and what is in short supply. The news section follows headlines from the trade and business press. My Journey is where I write about taking one of these drugs.
ClinicalTrials.gov · Drugs@FDA · FDA Drug Shortages · EMA · Europe PMC · Federal Register
Latest headlines
More headlines →Recent changes
All changes →Reporting in the next 90 days
22 trials reach their scheduled completion date within 90 days, 13 of them phase 3, 8,544 participants between them. Dates are filed by the sponsor and move often. Each one links to its own record and change history.
Full results calendar →How this works
Primary sources only
ClinicalTrials.gov, Drugs@FDA, the FDA Drug Shortage Database, the EMA register, Europe PMC and the Federal Register. Every field is taken directly from a source record and links back to it.
Refreshed every four hours
The whole set is re-fetched six times a day and the registry is diffed against the last snapshot, so a date that quietly moves is caught within hours instead of vanishing.
Not medical advice
This is a news and data tracker. No dosing, no treatment guidance, and no efficacy claims that aren’t attributed to a named study.
Method
Sources, editorial policy and how each page is built. Read the method →